New marker could help to identify heart attack patients most at risk

08 Feb 2018

1

A new study from the University of Sheffield has shown a new blood test could provide a clue as to why some patients are at higher risk of cardiovascular disease risk after suffering a heart attack.

The research may help scientists to identify new targets for reducing the risk and eventually lead to more effective treatments.

During the study, the team of researchers, led by Professor Rob Storey from the University of Sheffield's Department of Infection, Immunity and Cardiovascular Disease, analysed blood plasma samples from more than 4,300 patients with acute coronary syndrome as they were discharged from hospital.

They measured the maximum density of a clot and the time it took for the clot to break down - known as clot lysis time.

After adjustment for known clinical characteristics and risk factors, the study found that the patients with the longest clot lysis time had a 40-per cent increased risk of recurrent myocardial infarction or death due to cardiovascular disease.

Professor Storey, who is also academic director and an honorary consultant in the cardiology and cardiothoracic surgery directorate at the Sheffield Teaching Hospitals NHS Foundation Trust, says, "We have made huge strides over the last two decades in improving prognosis following heart attacks but there is still plenty of room for further improvement.

"Our findings provide exciting clues as to why some patients are at higher risk after heart attack and how we might address this with new treatments in the future."

The results, published in the European Heart Journal, showed novel therapies targeting fibrin clot lysis time may improve prognosis in patients with acute coronary syndrome.

Professor Storey adds, "We now need to press ahead with exploring possibilities for tailoring treatment to an individual's risk following a heart attack and testing whether drugs that improve clot lysis time can reduce this risk."

The Department of Infection, Immunity and Cardiovascular Disease at the University of Sheffield is a world-leading centre for pioneering discoveries which help to fight disease and inform inspiring teaching.

Latest articles

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Indians can now travel to 56 destinations without prior visa as passport ranking improves

Indians can now travel to 56 destinations without prior visa as passport ranking improves

CEO says EU’s IRIS2 must match Starlink on price and performance

CEO says EU’s IRIS2 must match Starlink on price and performance

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Opening the silos: India approves 3 million tonnes of wheat and product exports

Opening the silos: India approves 3 million tonnes of wheat and product exports

Capgemini beats 2025 revenue target as WNS acquisition boosts AI-driven growth

Capgemini beats 2025 revenue target as WNS acquisition boosts AI-driven growth

The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy

The deregulation “holy grail”: Trump EPA dismantles the legal bedrock of climate policy

France-backed Eutelsat beats revenue estimates as Starlink rivalry intensifies

France-backed Eutelsat beats revenue estimates as Starlink rivalry intensifies

Germany’s Stark reportedly crosses €1 billion valuation after fresh funding round

Germany’s Stark reportedly crosses €1 billion valuation after fresh funding round